Latest technology news and innovations
The Lindsay Clancy case highlights severe issues within the U.S. healthcare system, revealing the dangers of fragmented care and lack of communication among providers.
Recent findings confirm that recipients of gene-edited pig kidneys can later receive human organ transplants, marking a significant milestone for xenotransplantation.
The trial's deadlock raises significant concerns for mental health professionals, especially in the context of postpartum care.
A new round of pharmaceutical price cuts has been announced, but crucial details and implications remain unclear.
Novartis celebrates a significant milestone with its BTK inhibitor for multiple sclerosis, advancing the treatment landscape for the disease.
Recent drug pricing agreements expand to additional companies, while Novartis and Bristol Myers suspend cell therapy trials due to safety concerns.
The House is poised to vote on a funding bill that would block Trump's initiative to control federal research grants, targeting bipartisan support.
The NIH's recent proposal to limit the number of grants per researcher has sparked varied responses, highlighting ongoing concerns in the biomedical research arena.
Novartis' latest drug, pacibekitug, successfully reduces inflammation in a Phase 2 study, suggesting potential for cardiovascular treatment.
The Lindsay Clancy case highlights systemic flaws in maternal mental health care, raising concerns about its impact on psychiatrist willingness to treat patients.
AstraZeneca and Ionis' heart disease treatment faced an unexpected failure, raising concerns and interest among biotech competitors like Alnylam.
AstraZeneca's heart disease trial disappoints, showing no added benefit, while a court affirms FDA's handling of drug shortages for prominent diabetes treatments.
Cytokinetics is set to submit aficamten for FDA approval, potentially the first drug approved for non-obstructive hypertrophic cardiomyopathy.
AstraZeneca's recent heart disease trial failure underscores the effectiveness of stabilizers over silencers for treating ATTR-CM.
A year after resigning from the CDC, former staff members highlight ongoing issues and advocate for a reformed public health system free from political bias.
Roivant's new therapy, Lisraya, recently approved by the FDA, offers a non-steroidal option for treating dermatomyositis.
Health Secretary Robert F. Kennedy Jr. faces backlash over vaccine misinformation as PA confirms measles-related deaths; tensions escalate with state officials.
The FDA has approved Rasonque, a novel treatment for advanced pancreatic cancer, showing significant improvements in patient outcomes.
Pharmaceutical giants are poised to unveil data on new cardiovascular drugs targeting lipoprotein(a), marking a potential breakthrough in treatment.
In this edition of STAT's AI Prognosis: A conversation with Insitro CEO Daphne Koller on artificial intelligence in drug discovery, and other health AI news.